On September 29, 2026 Jecho Laboratories, Inc. reported it will present emerging preclinical data on JLC068, an affinity-modulated EGFR/TF bispecific antibody-drug conjugate (bsADC) at the 17th Annual World ADC Congress. EGFR and Tissue Factor (TF) are frequently co-overexpressed in solid tumors, including lung, breast, and pancreatic cancers. However, single antigen targeting ADCs have limited efficacy due to antigen heterogeneity and acquired resistance. Jecho has engineered a bsADC with TF-arm attenuation to spare normal tissue and widen the therapeutic window. JLC068 demonstrated robust efficacy across three xenograft models and was well-tolerated at efficacious doses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The World ADC Congress will be held October 12-15, 2026 in San Diego, CA.

Details on the presentation are below:

JLC068: A Differentiated Affinity-Modulated EGFR/TF Bispecific Antibody-Drug Conjugate

Abstract Presentation Number: 46
Session Time: Tuesday, October 13, 2026, 4 – 6 p.m. PST
Location: Town & Country Resort, San Diego, CA

(Press release, Jecho Laboratories, SEP 29, 2026, View Source [SID1234671149])